Format

Send to

Choose Destination
Clin Chem Lab Med. 2018 Sep 25;56(10):1715-1721. doi: 10.1515/cclm-2018-0116.

A design for external quality assessment for the analysis of thiopurine drugs: pitfalls and opportunities.

Robijns K1,2,3,4,5, van Luin M6,7, Jansen RTP8, Neef C4,6,9, Touw DJ6,10,11.

Author information

1
Dutch Foundation for Quality Assessment in Medical Laboratories (SKML), Section Therapeutic Drug Monitoring and Clinical Toxicology (KKGT), PO Box 43100, NL 2504 AC, The Hague, The Netherlands.
2
Central Hospital Pharmacy, The Hague, The Netherlands.
3
Haga Teaching Hospital, The Hague, The Netherlands.
4
CAPHRI School for Public Health and Primary Care, Maastricht University, Maastricht, The Netherlands.
5
Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre+, Maastricht, The Netherlands, Phone: +31-70-3217217, Fax: +31-70-3080140.
6
Dutch Foundation for Quality Assessment in Medical Laboratories (SKML), Section Therapeutic Drug Monitoring and Clinical Toxicology (KKGT), The Hague, The Netherlands.
7
Department of Clinical Pharmacy, Rijnstate Hospital, Arnhem, The Netherlands.
8
Dutch Foundation for Quality Assessment in Medical Laboratories (SKML), Nijmegen, The Netherlands.
9
Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre+, Maastricht, The Netherlands.
10
University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands.
11
University of Groningen, Groningen Research Institute of Pharmacy, Department of Pharmacokinetics Toxicology and Targeting, Groningen, The Netherlands.

KEYWORDS:

external quality assessment scheme; harmonization; thiopurine drugs

PMID:
30110249
DOI:
10.1515/cclm-2018-0116

Supplemental Content

Full text links

Icon for Sheridan PubFactory
Loading ...
Support Center